ImmuCell, Univax deal

ICCC (Portland, Maine) reacquired from UNVX the marketing rights for Crypto-GAM, a hyperimmune bovine immunoglobulin preparation to treat cryptosporidiosis in patients who are HIV positive. Development of CryptoGAM was one of the projects curtailed by the Rockville, Md., company as part of a restructuring.

The decision to focus Staph aureus product development on StaphGam was based in part on analysis of 25 percent of the data from recently completed Phase II trials of StaphVax, which showed that a more immunogenic dosage formulation must be developed (see Clinical Results, page B9). The cuts will reduce the company's monthly burn rate to $1.1 million from $2 million. UNVX had $22 million in cash as of March 31. ...